Karlijn van Loon

Karlijn van Loon

Auto-generated profile, based on publicly available information

Karlijn van Loon

Amsterdam UMC location Vrije Universiteit Amsterdam, Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJudy R. van Beijnum
Judy R. van Beijnum
EHElisabeth Huijbers
Elisabeth Huijbers
KLKarlijn van Loon
Karlijn van Loon
ABAthanasios Blanas
Athanasios Blanas
PAParvin Akbari
Parvin Akbari
AGArjan Griffioen
Arjan Griffioen
Anti-angiogenic cancer therapies possess immune-stimulatory properties by counteracting pro-angiogenic molecular mechanisms. We report that tumor endothelial cells ubiquitously overexpress and secrete the intermediate filament protein vimentin through type III unconventional secretion mechanisms. Extracellular vimentin is pro-angiogenic and functionally mimics VEGF action, while concomitantly acting as inhibitor of leukocyte-endothelial interactions. Antibody targeting of extracellular vimentin shows inhibition of angiogenesis in vitro and in vivo. Effective and safe inhibition of angiogenesis and tumor growth in several preclinical and clinical studies is demonstrated using a vaccination strategy against extracellular vimentin. Targeting vimentin induces a pro-inflammatory condition in the tumor, exemplified by induction of the endothelial adhesion molecule ICAM1, suppression of PD-L1, and altered immune cell profiles. Our findings show that extracellular vimentin contributes to immune suppression and functions as a vascular immune checkpoint molecule. Targeting of extracellular vimentin presents therefore an anti-angiogenic immunotherapy strategy against cancer.